F. Negro

Discipline

Economies et finances (3) Sociologie (1) Science politique (1) Gestion et management (1) Anthropologie biologique (1)

Type de document

Articles (35) Recensions (1) Colloques et conférences (1)

Co-auteur

Date

Source

Mot-clé

Hepatitis C (24) Hepatitis C virus (22) Treatment (21) infection (20) Patients (20) Infection (20) Patients (20) Human beings (18) Liver (18) thérapie (14) Therapeutics (14) maladie (12) maladie (12) adulte (10) Swiss (10) adulte (10) protéine (9) analyse (9) RNA (9) Expression (9) Analysis (9) association (8) Social groups (8) Fibrosis (8) Fibrosis (8) Ribavirin (7) Liver--Cancer (7) Hepatitis (7) Cancer (7) Antiviral agents (7)

Documents écrit par F. Negro (36) | parle de F. Negro (0)

The current and future burden of hepatitis B in Switzerland: a modelling study.
F. Negro et al. (5 juin 2023)
Scaling-up hepatitis C screening and treatment in Swiss outpatient psychiatric settings: A cost-effectiveness analysis.
F. Girardin et al.
Mir-21 Suppression Promotes Mouse Hepatocarcinogenesis.
M. Correia de Sousa et al. (4 oct. 2021)
Hepatitis C prevalences in the psychiatric setting: Cost-effectiveness of scaling-up screening and direct-acting antiviral therapy.
F. Girardin et al.
COVID-19 et hépatologie
F. Negro et al. (2 sept. 2020)
All-Cause Mortality and Causes of Death in the Swiss Hepatitis C Cohort Study (SCCS).
M. Roelens et al.
Impact of geographic origin on access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study.
M. Brezzi et al. (2019)
Treatment with direct-acting antivirals improves peripheral insulin sensitivity in non-diabetic, lean chronic hepatitis C patients.
G. Gastaldi et al. (2019)
BRIP1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease.
A. Oussalah et al. (8 sept. 2017)
Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030.
P. Bruggmann et al. (2017)
Characteristics of Foreign-Born Persons in the Swiss Hepatitis C Cohort Study: Implications for Screening Recommendations.
B. Bertisch et al. (2016)
Novel Approach Identifies SNPs in SLC2A10 and KCNK9 with Evidence for Parent-of-Origin Effect on Body Mass Index.
C.J. Hoggart et al. (2014)
Clinical significance of the CCR5delta32 allele in hepatitis C.
I. Morard et al. (2014)
Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes
E. Terczyńska-Dyla et al. (2014)
IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction.
S. Bibert et al. (2013)
Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection.
J. Söderholm et al. (2013)
Genetic Analyses Reveal a Role for Vitamin D Insufficiency in HCV-Associated Hepatocellular Carcinoma Development.
C.M. Lange et al. (2013)
Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection.
E. Patin et al.
Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma.
L. Kuske et al. (2012)
A Genetic Validation Study Reveals a Role of Vitamin D Metabolism in the Response to Interferon-Alfa-Based Therapy of Chronic Hepatitis C.
C.M. Lange et al. (2012)
Response Prediction in Chronic Hepatitis C by Assessment of IP-10 and IL28B-Related Single Nucleotide Polymorphisms.
M. Lagging et al. (2011)
The new EASL guidelines for the management of chronic hepatitis B infection adapted for Swiss physicians.
F. Bihl et al. (20 mars 2010)
IL28B polymorphism is significantly correlated with ifn anti-viral effectiveness already on first day of pegylated interferon-alpha and ribavirin therapy of chronic HCV infection
A. Neumann et al. (2010)
Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison study.
J.J. Gonvers et al. (2010)
Impact of international consensus guidelines on antiviral therapy of chronic hepatitis C patients in Switzerland.
K. Overbeck et al. (2010)

next